Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10

Cancer Letters

Volumn 245, Issue 1-2, 2007, Pages 195-204

  Hector, Suzanne ^a   Nava, Maria Enriqueta ^a   Clark, Kimberly ^a   Murphy, Michael ^a   Pendyala, Lakshmi ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

Cisplatin; Oxaliplatin; Platinum; Resistance

Indexed keywords

CISPLATIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; FLUOROURACIL; GAMMA GLUTAMYLTRANSFERASE; GLUTATHIONE; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 2; OXALIPLATIN; PLATINUM; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

ARTICLE; CANCER CELL CULTURE; CANCER RESISTANCE; CONTROLLED STUDY; CROSS RESISTANCE; DNA ADDUCT; DRUG ACCUMULATION; DRUG DNA BINDING; EXCISION REPAIR; HUMAN; HUMAN CELL; METASTASIS; NUCLEOTIDE SEQUENCE; OVARY CARCINOMA; PHENOTYPE; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL SURVIVAL; CISPLATIN; CLONE CELLS; DNA ADDUCTS; DNA-BINDING PROTEINS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, MULTIPLE; DRUG RESISTANCE, NEOPLASM; ENDONUCLEASES; FEMALE; GAMMA-GLUTAMYLTRANSFERASE; GLUTAMATE-CYSTEINE LIGASE; GLUTATHIONE; HUMANS; MEMBRANE TRANSPORT PROTEINS; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; ORGANOPLATINUM COMPOUNDS; OVARIAN NEOPLASMS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; XERODERMA PIGMENTOSUM GROUP A PROTEIN;

EID: 33845629728     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2006.01.007     Document Type: Article

References (47)

1. Pendyala L., and Creaven P.J. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Research 53 24 (1993) 5970-5976
2. Raymond E., Faivre S., Woynarowski J.M., and Chaney S.G. Oxaliplatin: mechanism of action and antineoplastic activity. Seminars in Oncology 25 2 Suppl 5 (1998) 4-12
3. Rixe O., Ortuzar W., Alvarez M., Parker R., Reed E., Paull K., et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the national cancer institute's anticancer drug screen panel. Biochemical Pharmacology 52 12 (1996) 1855-1865
4. Chollet P., Bensmaine M.A., Brienza S., Deloche C., Cure H., Caillet H., et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Annals of Oncology 7 10 (1996) 1065-1070
5. Woynarowski J.M., Chapman W.G., Napier C., Herzig M.C., and Juniewicz P. Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Molecular Pharmacology 54 5 (1998) 770-777
6. Hector S., Bolanowska-Higdon W., Zdanowicz J., Hitt S., and Pendyala L. In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemotherapy Pharmacology 48 5 (2001) 398-406
7. Saris C.P., van de Vaart P.J., Rietbroek R.C., and Blommaert F.A. In vitro formation of DNA adducts by cisplatin, lobaplatin and oxaliplatin in calf thymus DNA in solution and in cultured human cells. Carcinogenesis 17 12 (1996) 2763-2769
8. Woynarowski J.M., Faivre S., Herzig M.C., Arnett B., Chapman W.G., Trevino A.V., et al. Oxaliplatin-induced damage of cellular DNA. Molecular Pharmacology 58 5 (2000) 920-927
9. Andrews P.A. Mechanisms of acquired resistance to cisplatin. Cancer Treatment and Research 73 (1994) 217-248
10. Gosland M., Lum B., Schimmelpfennig J., Baker J., and Doukas M. Insights into mechanisms of cisplatin resistance and potential for its clinical reversal [Review]. Pharmacotherapy 16 1 (1996) 16-39
11. Chu G. Cellular responses to cisplatin. The roles of DNA-binding proteins and DNA repair [Review]. Journal of Biological Chemistry 269 2 (1994) 787-790
12. Johnson S.W., Laub P.B., Beesley J.S., Ozols R.F., and Hamilton T.C. Increased platinum-DNA damage tolerance is associated with cisplatin resistance and cross-resistance to various chemotherapeutic agents in unrelated human ovarian cancer cell lines. Cancer Research 57 5 (1997) 850-856
13. Reed E. Nucleotide excision repair and anti-cancer chemotherapy. Cytotechnology 27 (1998) 187-201
14. Sancar A. DNA excision repair. Annual Review of Biochemistry 65 (1997) 43-81 ([erratum appears in Annu Rev Biochem 1997;66:VII]. [Review])
15. Sancar A. Excision repair in mammalian cells. Journal of Biological Chemistry 270 (1995) 15915-15918
16. Taniguchi K., Wada M., Kohno K., Nakamura T., Kawabe T., Kawakami M., et al. A human canalicular multispecific organic anion transporter (cMOAT) gene is overexpressed in cisplatin-resistant human cancer cell lines with decreased drug accumulation. Cancer Research 56 (1996) 4124-4129
17. Liedert B., Materna V., Schadendorf D., Thomale J., and Lage H. Overexpression of cMOAT (MRP2/ABCC2) is associated with decreased formation of platinum-DNA adducts and decreased G2-arrest in melanoma cells resistant to cisplatin. Journal of Investigative Dermatology 121 1 (2003) 172-176
18. Fink D., Nebel S., Aebi S., Zheng H., Cenni B., Nehme A., et al. The role of DNA mismatch repair in platinum drug resistance. Cancer Research 56 21 (1996) 4881-4886
19. Fink D., Zheng H., Nebel S., Norris P.S., Aebi S., Lin T.P., et al. In vitro and in vivo resistance to cisplatin in cells that have lost DNA mismatch repair. Cancer Research 57 10 (1997) 1841-1845
20. Mamenta E.L., Poma E.E., Kaufmann W.K., Delmastro D.A., Grady H.L., and Chaney S.G. Enhanced replicative bypass of platinum-DNA adducts in cisplatin-resistant human ovarian carcinoma cell lines. Cancer Research 54 13 (1994) 3500-3505
21. Vaisman A., Varchenko M., Umar A., Kunkel T.A., Risinger J.I., Barrett J.C., et al. The role of hMLH1, hMSH3, and hMSH6 defects in cisplatin and oxaliplatin resistance: correlation with replicative bypass of platinum-DNA adducts. Cancer Research 58 16 (1998) 3579-3585
22. Mishima M., Samimi G., Kondo A., Lin X., and Howell S.B. The cellular pharmacology of oxaliplatin resistance. European Journal of Cancer 38 10 (2002) 1405-1412
23. El-akawi Z., Zdanowicz J., Creaven P.J., Abu-hadid M., Perez R., and Pendyala L. Induction of gamma-glutamyl transpeptidase mRNA by platinum complexes in a human ovarian carcinoma cell line. Oncology Research 8 10-11 (1996) 415-423
24. El-akawi Z., Abu-hadid M., Perez R., Glavy J., Zdanowicz J., Creaven P.J., et al. Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer Letters 105 1 (1996) 5-14
25. Samimi G., Manorek G., Castel R., Breaux J.K., Cheng T.C., Berry C.C., et al. cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance. Cancer Chemotherapy and Pharmacology 55 1 (2005) 1-11
26. Varma R.R., Hector S.M., Greco W.R., Hawthorn L., and Pendyala L. Gene expression profiling of a clonal isolate of oxaliplatin resistant A2780 ovarian carcinoma cell line A2780/C10. Oncology Reports 14 (2005) 925-932
27. Glavy J. Isolation and Preliminary Characterization of Oxaliplatin Resistant Sublines of A2780 Human Ovarian Carcinoma Cell Line (1993), MS Thesis, Roswell Park Cancer Institute/University at Buffalo, Buffalo, NY
28. Rubinstein L.V., Shoemaker R.H., Paull K.D., Simon R.M., Tosini S., Skehan P., et al. Comparison of in vitro anticancer-drug-screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. Journal of the National Cancer Institute 82 13 (1990) 1113-1118
29. Fahey R.C., and Newton G.L. Determination of low-molecular-weight thiols using monobromobimane fluorescent labeling and high-performance liquid chromatography. Methods in Enzymology 143 (1987) 85-96
30. Levi F., Metzger G., Massari C., and Milano G. Oxaliplatin: pharmacokinetics and chronopharmacological aspects [Review]. Clinical Pharmacokinetics 38 1 (2000) 1-21
31. Smith P.F., Booker B., Pendyala L., Leichman C.G., Berdzik J., Muffley M., et al. Pharmokinetic Modeling of oxalipaltin with and without 5-FU and radiation. Proceedings of the American Association for Cancer Research 42 (2002) 542
32. Luo F.R., Wyrick S.D., and Chaney S.G. Cytotoxicity, cellular uptake, and cellular biotransformations of oxaliplatin in human colon carcinoma cells. Oncology Research 10 11-12 (1998) 595-603
33. Pendyala L., Kidani Y., Perez R., Wilkes J., Bernacki R.J., and Creaven P.J. Cytotoxicity, cellular accumulation and DNA binding of oxaliplatin isomers. Cancer Letters 97 2 (1995) 177-184
34. Kalluri R., and Neilson E.G. Epithelial-mesenchymal transition and its implications for fibrosis. Journal of Clinical Investigation 112 (2003) 1776-1784
35. Elliott T., and Sethi T. Integrins and extracellular matrix: a novel mechanism of multidrug resistance [Review]. Expert Review of Anticancer Therapy 2 4 (2002) 449-459
36. Hector S., Porter C.W., Kramer D.L., Clark K., Prey J., Kisiel N., et al. Polyamine catabolism in platinum drug action: Interactions between oxaliplatin and the polyamine analogue N′,N″-diethylnorspermine at the level of spermidine/spermine N′-acetyltransferase. Molecular Cancer Therapeutics 3 7 (2004) 813-822
37. Raymond E., Faivre S., Chaney S., Woynarowski J., and Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Molecular Cancer Therapeutics 1 3 (2002) 227-235
38. Scheeff E.D., Briggs J.M., and Howell S.B. Molecular modeling of the intrastrand guanine-guanine DNA adducts produced by cisplatin and oxaliplatin. Molecular Pharmacology 56 3 (1999) 633-643
39. ′-acetyltransferase as a determinant of oxaliplatin drug action and resistance. Proceedings of the American Association for Cancer Research 46 (2005) 1383
40. Safaei R., Holzer A.K., Katano K., Samimi G., and Howell S.B. The role of copper transporters in the development of resistance to Pt drugs [Review]. Journal of Inorganic Biochemistry 98 10 (2004) 1607-1613
41. Samimi G., Safaei R., Katano K., Holzer A.K., Rochdi M., Tomioka M., et al. Increased expression of the copper efflux transporter ATP7A mediates resistance to cisplatin, carboplatin, and oxaliplatin in ovarian cancer cells. Clinical Cancer Research 10 14 (2004) 4661-4669
42. Sherman-Baust C.A., Weeraratna A.T., Rangel L.B., Pizer E.S., Cho K.R., Schwartz D.R., et al. Remodeling of the extracellular matrix through overexpression of collagen VI contributes to cisplatin resistance in ovarian cancer cells. Cancer Cell 3 4 (2003) 377-386
43. Rintoul R.C., and Sethi T. The role of extracellular matrix in small-cell lung cancer [Review]. Lancet Oncology 2 7 (2001) 437-442
44. Sethi T., Rintoul R.C., Moore S.M., MacKinnon A.C., Salter D., Choo C., et al. Extracellular matrix proteins protect small cell lung cancer cells against apoptosis: a mechanism for small cell lung cancer growth and drug resistance in vivo. Nature Medicine 5 6 (1999) 662-668
45. Rintoul R.C., and Sethi T. Extracellular matrix regulation of drug resistance in small-cell lung cancer [Review]. Clinical Science 102 4 (2002) 417-424
46. Tannock I.F., Lee C.M., Tunggal J.K., Cowan D.S.M., and Egorin M.J. Limited penetration of anticancer drugs through tumor tissue: a potential cause of resistance of solid tumors to chemotherapy. Clinical Cancer Research 8 (2002) 878-884
47. Johnson S.W., Perez R.P., Godwin A.K., Yeung A.T., Handel L.M., Ozols R.F., and Hamilton T.C. Role of platinum-DNA adduct formation and removal in cisplatin resistance in human ovarian cancer cell lines. Biochemical Pharmacology 47 4 (1994) 689-697